20 December 2019
Visiongain’s new report the Head and Neck Cancer Drugs Market Report 2019-2029: Forecasts by Treatment (Surgery, Radiation Therapy, Chemotherapy, Immunotherapy), by Therapeutic Class (PD Inhibitors, EGFR Inhibitors, Microtubule Inhibitors), by Distribution Channel (Hospitals, Online Providers, Drug stores & retail pharmacies), plus analysis of leading companies operating in the global head and neck cancer drugs market.
Increasing global geriatric population, growing prevalence of neck and head cancer, and increasing tobacco and alcohol consumption is expected to increase global head and neck cancer drugs market over the projected period. In 2019, the global head and neck cancer drugs market was valued at $963 million and is expected to reach $2.58 billion by 2029 at a CAGR of 10.3% over the projected period.
According to the World Health Organization, tobacco kills more than 8 million people each year. More than 7 million of those deaths are the result of direct tobacco use while around 1.2 million are the result of non-smokers being exposed to second-hand smoke. Tobacco consumption is ranked as the leading cause of illness, death, and impoverishment. Increasing tobacco consumption has increased the prevalence of head and neck cancer over the past few years and the trend is expected to continue over the course of time.
Increasing geriatric population in developed as well as developing economies are expected to prone more towards chronic diseases, which in turn is expected to drive the head and neck cancer drugs market. Some identified disruptive drugs are Opdivo, Keytruda, Imfinzi, Bavencio, Yervoy, Tremelimumab, Buparlisib, and Epacadostat.
List of head and neck cancer drugs providers identified in this report are Bristol-Myers Squibb, Merck, Sanofi, Eli Lilly, AstraZeneca Plc., F. Hoffmann-La Roche Ltd., Fresenius Medical Care AG & Co. KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Limited.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.
19 April 2022
The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet
13 April 2022
The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.
13 April 2022
Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.